Notably, TNF‐α antagonists like infliximab have been tested in depression: a randomized controlled trial found that while infliximab overall did not outperform placebo, it significantly improved mood symptoms in the high baseline inflammation subgroup (CRP > 5 mg/L) [693]. Here, TNF is linked to major depressive disorder.